CN1903259A - Method for extraction and separation of moutan bark - Google Patents
Method for extraction and separation of moutan bark Download PDFInfo
- Publication number
- CN1903259A CN1903259A CN 200510012275 CN200510012275A CN1903259A CN 1903259 A CN1903259 A CN 1903259A CN 200510012275 CN200510012275 CN 200510012275 CN 200510012275 A CN200510012275 A CN 200510012275A CN 1903259 A CN1903259 A CN 1903259A
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- component
- minutes
- collected
- eluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000926 separation method Methods 0.000 title claims description 41
- 238000000605 extraction Methods 0.000 title claims description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 192
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 151
- 239000000243 solution Substances 0.000 claims description 104
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 69
- 239000003480 eluent Substances 0.000 claims description 60
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 46
- 239000007864 aqueous solution Substances 0.000 claims description 38
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 30
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 claims description 22
- 238000004262 preparative liquid chromatography Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 21
- 238000010992 reflux Methods 0.000 claims description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
- 238000005516 engineering process Methods 0.000 claims description 20
- 239000000741 silica gel Substances 0.000 claims description 20
- 229910002027 silica gel Inorganic materials 0.000 claims description 20
- 229960001866 silicon dioxide Drugs 0.000 claims description 20
- 230000008859 change Effects 0.000 claims description 18
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 claims description 17
- 229940074391 gallic acid Drugs 0.000 claims description 16
- 235000004515 gallic acid Nutrition 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000012567 medical material Substances 0.000 claims description 14
- VIWQCBZFJFSCLC-UXPYWIADSA-N Benzoyloxypaeoniflorin Natural products O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@]23[C@]4(COC(=O)c5ccc(O)cc5)[C@@H]5OC2(C)C[C@@](O)(O5)[C@@H]4C3)O1)c1ccccc1 VIWQCBZFJFSCLC-UXPYWIADSA-N 0.000 claims description 12
- VIWQCBZFJFSCLC-HRCYFWENSA-N beta-benzoyloxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-HRCYFWENSA-N 0.000 claims description 12
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 claims description 10
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 claims description 10
- 238000000227 grinding Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000003208 petroleum Substances 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- 238000010828 elution Methods 0.000 claims description 8
- 239000009835 oxypaeoniflora Substances 0.000 claims description 8
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 claims description 8
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 claims description 8
- 229930190084 Mudanoside Natural products 0.000 claims description 6
- VIWQCBZFJFSCLC-QFZPXPOBSA-N mudanpioside c Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-QFZPXPOBSA-N 0.000 claims description 6
- KLFIUQCKSSAFFU-QHOIGUMUSA-N Galloylpaeoniflorin Natural products O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@]23[C@]4(COC(=O)c5ccccc5)[C@@H]5O[C@@]2(C)C[C@@](O)(O5)[C@@H]4C3)O1)c1cc(O)c(O)c(O)c1 KLFIUQCKSSAFFU-QHOIGUMUSA-N 0.000 claims description 5
- KLFIUQCKSSAFFU-ANNBSXMPSA-N galloylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=C(O)C(O)=C(O)C=2)O1)O)C)OC(=O)C1=CC=CC=C1 KLFIUQCKSSAFFU-ANNBSXMPSA-N 0.000 claims description 5
- SDCMIWDDPOQVAS-BWDMLNMCSA-N paeonidanin Chemical compound O([C@]12C[C@H]3C(=O)C[C@]1(C)CC([C@]23COC(=O)C=1C=CC=CC=1)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SDCMIWDDPOQVAS-BWDMLNMCSA-N 0.000 claims description 5
- 229930186559 paeonidanin Natural products 0.000 claims description 5
- RCIAZDQVOCMCHH-OJMZZINESA-N COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@@H](OC(=O)C=4C=C(O)C(O)=C(O)C=4)CO3)O)O2)O)=C1 Chemical compound COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@@H](OC(=O)C=4C=C(O)C(O)=C(O)C=4)CO3)O)O2)O)=C1 RCIAZDQVOCMCHH-OJMZZINESA-N 0.000 claims description 3
- RCIAZDQVOCMCHH-UESDTVSWSA-N Suffruticoside C Natural products O=C(O[C@H]1[C@H](O)[C@H](O)[C@H](OC[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc3c(C(=O)C)ccc(OC)c3)O2)OC1)c1cc(O)c(O)c(O)c1 RCIAZDQVOCMCHH-UESDTVSWSA-N 0.000 claims description 3
- CQQDDGSILZDABB-RHNSDZJESA-N Suffruticoside D Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](Oc2c(C(=O)C)ccc(OC)c2)O[C@@H]1OC[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)CO1)c1cc(O)c(O)c(O)c1 CQQDDGSILZDABB-RHNSDZJESA-N 0.000 claims description 3
- IIYNOSFQRKUHOL-FZOOHXBBSA-N [(2r,3s,4r,5r,6s)-6-(2-acetyl-5-methoxyphenoxy)-2-[[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]-4,5-dihydroxyoxan-3-yl] 3,4,5-trihydroxybenzoate Chemical compound COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H](CO[C@H]3[C@@H]([C@@](O)(CO)CO3)O)O2)O)=C1 IIYNOSFQRKUHOL-FZOOHXBBSA-N 0.000 claims description 3
- QNVPMKAFCVXMFH-NDDHQHNUSA-N [(3s,4r,5r)-5-[[(2r,3s,4s,5r,6s)-6-(2-acetyl-5-methoxyphenoxy)-3,4,5-trihydroxyoxan-2-yl]methoxy]-3,4-dihydroxyoxolan-3-yl]methyl 3,4,5-trihydroxybenzoate Chemical compound COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@](O)(COC(=O)C=4C=C(O)C(O)=C(O)C=4)CO3)O)O2)O)=C1 QNVPMKAFCVXMFH-NDDHQHNUSA-N 0.000 claims description 3
- ICDRIPCQQSUIDZ-HRCYFWENSA-N mudanpioside h Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC(O)=CC=2)O1)O)C)OC(=O)C1=CC=C(O)C=C1 ICDRIPCQQSUIDZ-HRCYFWENSA-N 0.000 claims description 3
- QNVPMKAFCVXMFH-UHFFFAOYSA-N suffruticoside A Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(COC3C(C(O)(COC(=O)C=4C=C(O)C(O)=C(O)C=4)CO3)O)O2)O)=C1 QNVPMKAFCVXMFH-UHFFFAOYSA-N 0.000 claims description 3
- IIYNOSFQRKUHOL-UHFFFAOYSA-N suffruticoside B Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(COC3C(C(O)(CO)CO3)O)O2)O)=C1 IIYNOSFQRKUHOL-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 37
- 229940079593 drug Drugs 0.000 abstract description 19
- 238000012216 screening Methods 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 abstract description 4
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 abstract description 2
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 40
- 210000000582 semen Anatomy 0.000 description 35
- 229960000583 acetic acid Drugs 0.000 description 20
- 239000012362 glacial acetic acid Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- 241000628997 Flos Species 0.000 description 17
- 239000012141 concentrate Substances 0.000 description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 240000005001 Paeonia suffruticosa Species 0.000 description 11
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 11
- 101710088194 Dehydrogenase Proteins 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 239000012531 culture fluid Substances 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- -1 hydroxypaeoniflorin Chemical compound 0.000 description 7
- QJYNZEYHSMRWBK-NIKIMHBISA-N 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose Chemical compound OC1=C(O)C(O)=CC(C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 QJYNZEYHSMRWBK-NIKIMHBISA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- AVIUTYMRHHBXPB-UXXRCYHCSA-N Paeonoside Natural products COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 AVIUTYMRHHBXPB-UXXRCYHCSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000003725 endotheliocyte Anatomy 0.000 description 5
- AVIUTYMRHHBXPB-UHFFFAOYSA-N glucopaeonol Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(CO)O2)O)=C1 AVIUTYMRHHBXPB-UHFFFAOYSA-N 0.000 description 5
- XFFQVRFGLSBFON-DEFKTLOSSA-N kaempferol 3,7-di-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 XFFQVRFGLSBFON-DEFKTLOSSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229920002793 1,2,3,4,6-Pentagalloyl glucose Polymers 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000003954 umbilical cord Anatomy 0.000 description 3
- RATQVALKDAUZBW-XPMKZLBQSA-N 1,2,3,6-tetrakis-O-galloyl-beta-D-glucose Chemical compound C([C@@H]1[C@H]([C@@H]([C@@H](OC(=O)C=2C=C(O)C(O)=C(O)C=2)[C@H](OC(=O)C=2C=C(O)C(O)=C(O)C=2)O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 RATQVALKDAUZBW-XPMKZLBQSA-N 0.000 description 2
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical class NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 241000209020 Cornus Species 0.000 description 2
- 241000218176 Corydalis Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- RATQVALKDAUZBW-UHFFFAOYSA-N 1(beta),2,3,6-tetra-O-galloylglucose Natural products O1C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1COC(=O)C1=CC(O)=C(O)C(O)=C1 RATQVALKDAUZBW-UHFFFAOYSA-N 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- 241000242759 Actiniaria Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000563984 Ampelopsis Species 0.000 description 1
- 241000746375 Andrographis Species 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 241000489492 Arisaema Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000255791 Bombyx Species 0.000 description 1
- 241000959626 Calvatia Species 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 241001649190 Campsis Species 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 241000903946 Clematidis Species 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 239000008589 Cortex Fraxini Substances 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 235000008597 Diospyros kaki Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 244000268590 Euryale ferox Species 0.000 description 1
- 235000006487 Euryale ferox Nutrition 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 1
- 235000015511 Liquidambar orientalis Nutrition 0.000 description 1
- 241000283956 Manis Species 0.000 description 1
- 241000217407 Margaritifera Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- 241001250596 Pleione Species 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 244000044425 Quisqualis indica Species 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 239000004870 Styrax Substances 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241001643642 Viticis Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000009670 cang er zi wan Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 239000009969 fructus bruceae Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940056582 human hair preparation Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000009806 pulsatillae Substances 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000009286 sanguis draxonis Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A standardized extracting and separating method for extracting the chemical components from a Chinese-medicinal material to maximal extent and further separating them to obtain the chemical components with different polarities is disclosed. To be specific, the paeonol is divided into several chemical components according to their polarities. Each component contains only several main compounds. Said components can constitute a component library used for medicine screening to find out novel medicines.
Description
Technical field
The invention belongs to field of medicaments, particularly relate to Cortex Moutan extraction, separation method.
Background technology
At present, in the world, Chinese herbal medicine all has certain market, along with people increasing and the aging of population to the health requirements level of understanding, sub-health stateization, people thirst for back to nature more, utilize the high Drug therapy of pure natural degree, prevent some chemical synthetic drugs cann't be solved problem, so the application of natural plant exceeds the background of its original traditional national culture.From natural drug, seek the little and inexpensive medicine of side effect and become the target that countries in the world pharmaceutical manufacturer is chased.The European Community has carried out unified legislation to medical herbs, state medical herbs status such as Canada and Australia have legalized, U.S. government has also drafted the plant amedica management method, the compound recipe mix preparation that begins to accept natural drug is as curative, and these provide good international environment for Chinese medicine enters international medical market as curative.On the other hand, along with the quickening of global economic integration progress, particularly China becomes a full member of WTO, and Chinese Medicine market incorporates the breadth and depth of international medical big market and will further aggravate.Face the enormous impact of Asian countries's traditional medicine product such as the keen competition of powerful transnational medical group and Japan, Korea S, India, Thailand and European countries' plant amedica such as Germany, France, numerous products that China's Chinese medicine produces are owing to still can not meet the standard of international medical market and requirement and being kept outside of the door.
The standardization that Chinese crude drug extracts and the standardization of Chinese medicinal preparation method are that Chinese patent medicine moves towards the international market or really realizes big industrial key link, also are that the scientific research personnel of Chinese Medicine worker and foreign study natural plant makes great efforts the direction studied always.Extracting method about Chinese medicine is the emphasis of field of Chinese medicines research at present, the scientific research personnel focuses on the more effective ingredient which kind of method of employing could obtain with the sight of research always from Chinese crude drug, therefore the situation that present Chinese crude drug extracts is: extraction, separation method at different its effective ingredient of Chinese crude drug are also different, and the extraction of adopting different extraction, separation methods to need a large amount of different extractions and separation equipment to be used to support Chinese crude drug at different Chinese crude drug, separate, this is unsuitable for, and Chinese crude drug extracts, isolating standardization.
Cortex Moutan another name Cortex Moutan, unpeeled CORTEX MOUTAN, wooden Radix Paeoniae, Luoyang flower are the root bark of Paeoniaceae plant Paeonia suffruticosa.What Paeonia suffruticosa was written into ancient books and records the earliest as medicine is Shennong's Herbal.The mechanism that bright Ni Zhumo " book on Chinese herbal medicine converges and says " controls the gas treating blood disorders to Paeonia suffruticosa has been done comparatively detailed elaboration: " Cortex Moutan clears away heart-fire, and supports kidney, regulating liver-QI, and sharp envelope, and control four through blood system volt fire, the gas medicine is also in the blood.It is kind that to control woman's blood vessels stagnant blood in obstructed and puerperal more than.Control epistaxis, haematemesis, metrorrhagia, pouring blood again, fall and pounce on blood stasis, all blood for sick, system can be controlled it.Cover its gas perfume (or spice), but perfume (or spice) promoting the circulation of QI and promoting the circulation of blood; Its bitter in the mouth, hardship can the therapeutic method to keep the adverse QI flowing downwardss and are stopped blooding; It is cool in nature, and cold can be with blood and hemopoietic; Its flavor is hot again, and suffering can push away Chen Xueer and cause fresh blood also.So Zhen Quanfang controls woman's blood, Yin Re and with withered, lumbar vertebrae pain, the fever at night excessive thirst heavily adds Cortex Moutan with four things and tests most.”
Modern study indicates that Cortex Moutan has clearing away heat and cooling blood, the effect of promoting blood circulation to remove blood stasis.Be used for the treatment of the epidemic febrile disease pathogenic heat attacking blood system in febrile diseases, send out speckle, tell nosebleed, the calentura later stage, hot Fu Yin divided heating, deficiency of YIN osteopyrexia and fever, and amenorrhea due to stagnation of blood, dysmenorrhea, carbuncle sore tumefacting virus falls and pounces on the pain of injury, diseases such as rheumatism pyretic arthralgia.The main chemical compositions of Cortex Moutan is paeonol, paeoniflorin, oxypaeoniflorin, hydroxypaeoniflorin, benzoylpaeoniflorin and benzoyl hydroxypaeoniflorin, volatile oil, and benzoic acid, plant sterol, sucrose, glucose, arabinose etc.And paeoniflorin, oxypaeoniflorin, benzoylpaeoniflorin are main effective ingredient.
How to determine a kind of extraction, separation criterion method, the active constituents of medicine in the Cortex Moutan not only can be extracted fully, can also further separate the active constituents of medicine that is obtained by separation method.The establishment of this extraction, separation criterionization is that present Chinese medicine is realized modern key factor.
Summary of the invention
The object of the present invention is to provide the extraction of a kind of Cortex Moutan mark, separation criterion method.Exactly Cortex Moutan extract is divided into fractions specifically, each component comprises several main compound, has constituted a medical material component pool by these medical material components.Can carry out drug screening to the medical material component pool, thereby find new drug.
In order to realize Cortex Moutan extraction, isolating modernization, standardization, the inventor is by a large amount of tests, extraction, separation method to the effective ingredient of present Cortex Moutan are concluded and are put in order, with seek a kind of can standardized extracting method, promptly under this extraction conditions, adopt this extraction standardized method that Cortex Moutan is extracted, can obtain the effective ingredient in the Chinese medicine to greatest extent; By the separation criterion method, the active constituents of medicine that extracts is further separated.
Cortex Moutan of the present invention extracts, the separation criterion method is that the inventor passes through test, after Chinese crude drug adopts different extracting method to compare simply together, and the resulting Cortex Moutan extraction separation standardized method that is suitable for suitability for industrialized production.
The present invention can implement through the following steps:
(1) extraction process: take by weighing the Cortex Moutan medical material, with its grinding and sieving, add ethyl acetate and ethanol then, heating extraction gets extracting solution fr.1.Add ethanol in medicinal residues, heating extraction gets extracting solution fr.2.Add entry in medicinal residues at last, heating extraction gets extracting solution fr.3.
(2) separating technology: after extracting solution fr.1 is condensed into extractum, use silica gel mixed sample, adopt normal phase silicagel column that it is separated, at first use petroleum ether and ethyl acetate as mobile phase, get eluent fr.4, change chloroform and methanol then, get eluent fr.5 as mobile phase, use methanol as mobile phase at last, get eluent fr.6.After extracting solution fr.2 is condensed into extractum, with sample on the dissolve with methanol, adopt the ODS-C18 post that it is separated, the methanol of at first using low concentration is as mobile phase, get eluent fr.7, the methanol that changes intermediate concentration then gets eluent fr.8 as mobile phase, use pure methanol solution as mobile phase at last, get eluent fr.9.
(3) preparation separating technology: continue to separate fr.5 and the fr.8 that obtains in the previous process with preparative liquid chromatography.Chromatographic column is semi-preparative column (Lichrospher C18; 10.0mm * 250mm, 5 μ m), mobile phase is water and acetonitrile, gradient elution is collected fraction in the corresponding time period, obtains to have passed through further isolating each component.
Preferred the present invention can implement through the following steps:
(1) extraction process: take by weighing the Cortex Moutan medical material, with its grinding and sieving, adding 5～12 times of amount volume ratios then is 1: 1 ethyl acetate and ethanol, and reflux 0.5～3 hour is extracted 1～3 time, and merging filtrate gets extracting solution fr.1.Add 5～12 times of amount 70% ethanol in medicinal residues, reflux 0.5～3 hour is extracted 1～3 time, and merging filtrate gets extracting solution fr.2.Add entry in medicinal residues at last, reflux 0.5～3 hour is extracted 1～3 time, and merging filtrate gets extracting solution fr.3.
(2) separating technology: after extracting solution fr.1 is condensed into extractum, use silica gel mixed sample, adopt normal phase silicagel column that it is separated, be that 50: 1 petroleum ether and ethyl acetate are as mobile phase at first with volume ratio, eluent fr.4, change volume ratio then and be 10: 1 chloroform and methanol as mobile phase, eluent fr.5, use methanol as mobile phase at last, get eluent fr.6.After extracting solution fr.2 is condensed into extractum, with sample on 2～10% dissolve with methanol, adopt the ODS-C18 post that it is separated, at first use 2～10% methanol as mobile phase, get eluent fr.7, change 40～80% methanol then, get eluent fr.8 as mobile phase, use 100% methanol solution as mobile phase at last, get eluent fr.9.
(3) preparation separating technology: continue to separate fr.5 and the fr.8 that obtains in the previous process with preparative liquid chromatography.Chromatographic column is semi-preparative column (Lichrospher C18; 10.0mm * 250mm, 5 μ m), mobile phase is water and acetonitrile, and gradient elution, flow velocity are 3ml/min, and column temperature is a room temperature, collects fraction in the corresponding time period, obtains through further isolating each component.
Best the present invention can implement through the following steps:
(1) extraction process: take by weighing the Cortex Moutan medical material, with its grinding and sieving, adding 8 times of amount volume ratios then is 1: 1 ethyl acetate and ethanol, and reflux 1 hour is extracted 2 times, and merging filtrate gets extracting solution fr.1.Add 8 times of amount 70% ethanol in medicinal residues, reflux 1 hour is extracted 2 times, and merging filtrate gets extracting solution fr.2.Add entry in medicinal residues at last, reflux 1 hour is extracted 2 times, and merging filtrate gets extracting solution fr.3.
(2) separating technology: fr.1 is condensed into extractum with extracting solution, use silica gel mixed sample, adopt normal phase silicagel column that it is separated, be that 50: 1 petroleum ether and ethyl acetate are as mobile phase at first with volume ratio, eluent fr.4, change volume ratio then and be 10: 1 chloroform and methanol as mobile phase, eluent fr.5, use methanol as mobile phase at last, get eluent fr.6.Fr.2 is condensed into extractum with extracting solution, with sample on 5% dissolve with methanol, adopt the ODS-C18 post that it is separated, at first use 5% methanol as mobile phase, get eluent fr.7, change 60% methanol then, get eluent fr.8 as mobile phase, use 100% methanol solution as mobile phase at last, get eluent fr.9.
(3) preparation separating technology: in order from step (2), to obtain fr.5 and the more concrete effective ingredient of fr.8 in the Cortex Moutan extract, continue to separate fr.5 and fr.8 among the present invention with preparative liquid chromatography.
The fr.5 separation condition: chromatographic column is semi-preparative column (the Lichrospher C18 of Chinese nation; 10.0mm * 250mm, 5 μ m), mobile phase is water (A) and acetonitrile (B), and flow velocity is 3ml/min, and column temperature is a room temperature.The gradient elution program is as follows:
In the time of 0 minute, mobile phase A is that 80% aqueous solution, Mobile phase B are 20% acetonitrile solution;
In the time of 40 minutes, mobile phase A is that 20% aqueous solution, Mobile phase B are 80% acetonitrile solution;
In the time of 50 minutes, mobile phase A is that 5% aqueous solution, Mobile phase B are 95% acetonitrile solution.
The fr.5 separating resulting: the component and the corresponding acquisition time that are obtained by the preparative liquid chromatography separation are as follows: collection in 4.0～7.6 minutes obtains component fr.51,7.6 collected and obtain component fr.52 in～9.7 minutes, 9.7 collected and obtain component fr.53 in～14.2 minutes, 14.2 collected and obtain component fr.54 in～18.4 minutes, 21.8 collected and obtain component fr.55 in～26.5 minutes, 21.8 collected and obtain component fr.56 in～26.5 minutes, 26.5 collected and obtain component fr.57 in～30.3 minutes, 30.3 collected and obtain component fr.58 in～35.5 minutes, collection in 35.5～45 minutes obtains component fr.59.
The fr.8 separation condition: chromatographic column is semi-preparative column (the Lichrospher C18 of Chinese nation; 10.0mm * 250mm, 5 μ m), mobile phase is water (A) and acetonitrile (B), and flow velocity is 3ml/min, and column temperature is a room temperature.The gradient elution program is as follows:
In the time of 0 minute, mobile phase A is that 90% aqueous solution, Mobile phase B are 10% acetonitrile solution;
In the time of 8 minutes, mobile phase A is that 81% aqueous solution, Mobile phase B are 19% acetonitrile solution;
In the time of 60 minutes, mobile phase A is that 65% aqueous solution, Mobile phase B are 35% acetonitrile solution;
In the time of 70 minutes, mobile phase A is that 95% aqueous solution, Mobile phase B are 5% acetonitrile solution.
The fr.8 separating resulting: the component and the corresponding acquisition time that are obtained by the preparative liquid chromatography separation are as follows: collection in 4.0～7.7 minutes obtains component fr.81,7.7 collected and obtain component fr.82 in～10.7 minutes, 10.7 collected and obtain component fr.83 in～15.8 minutes, 15.8 collected and obtain component fr.84 in～18.8 minutes, 18.8 collected and obtain component fr.85 in～23.2 minutes, 23.2 collected and obtain component fr.86 in～27.4 minutes, 27.4 collected and obtain component fr.87 in～33.1 minutes, 33.1 collected and obtain component fr.88 in～40.2 minutes, 40.2 collected and obtain component fr.89 in～44.4 minutes, 44.4 collected and obtain component fr.810 in～48.5 minutes, 48.5 collected and obtain component fr.811 in～58 minutes, collected in 58～67 minutes and obtain component fr.812, collection in 67～75 minutes obtains component fr.813.
In order to obtain concrete Cortex Moutan effective ingredient, best extraction of the present invention, separation method are:
(1) extraction process: take by weighing Cortex Moutan medical material 250g, with its grinding and sieving, adding 8 times of amount volume ratios then is 1: 1 ethyl acetate and ethanol, and reflux 1 hour is extracted 2 times, and merging filtrate gets extracting solution fr.1.Add 8 times of amount 70% ethanol in medicinal residues, reflux 1 hour is extracted 2 times, and merging filtrate gets extracting solution fr.2.Add entry in medicinal residues at last, reflux 1 hour is extracted 2 times, and merging filtrate gets extracting solution fr.3.
(2) separating technology: with extracting solution fr.1 concentrate 22g extractum, use silica gel mixed sample, adopt normal phase silicagel column that it is separated, at first with volume ratio be 50: 1 petroleum ether and ethyl acetate as mobile phase, eluent fr.4, change volume ratio then and be 10: 1 chloroform and methanol as mobile phase, get eluent fr.5, concentrate the 6.2g sample, use methanol as mobile phase at last, eluent fr.6.With extracting solution fr.2 concentrate 55g extractum, with sample on 5% dissolve with methanol, adopt the ODS-C18 post that it is separated, at first use 5% methanol as mobile phase, get eluent fr.7, change 60% methanol then as mobile phase, get eluent fr.8, concentrate the 2.6g sample, use 100% methanol solution as mobile phase at last, eluent fr.9.
(3) preparation separating technology: in order from step (2), to obtain fr.5 and the more concrete effective ingredient of fr.8 in the Cortex Moutan extract, continue to separate fr.5 and fr.8 among the present invention with preparative liquid chromatography.
The fr.5 separation condition: chromatographic column is semi-preparative column (the Lichrospher C18 of Chinese nation; 10.0mm * 250mm, 5 μ m), mobile phase is water (A) and acetonitrile (B), and flow velocity is 3ml/min, and column temperature is a room temperature.The gradient elution program is as follows:
In the time of 0 minute, mobile phase A is that 80% aqueous solution, Mobile phase B are 20% acetonitrile solution;
In the time of 40 minutes, mobile phase A is that 20% aqueous solution, Mobile phase B are 80% acetonitrile solution;
In the time of 50 minutes, mobile phase A is that 5% aqueous solution, Mobile phase B are 95% acetonitrile solution.
Fr.5 separating resulting: get component fr.5 1.4g, dissolve with ethanol sample introduction with 10%, the component and the corresponding acquisition time that are obtained by the preparative liquid chromatography separation are as follows: collection in 4.0～7.6 minutes obtains component fr.51 0.16g, 7.6 collected and obtain component fr.52 0.11g in～9.7 minutes, 9.7 collected and obtain component fr.53 0.32g in～14.2 minutes, 14.2 collected and obtain component fr.540.13g in～18.4 minutes, 21.8 collected and obtain component fr.55 0.21g in～26.5 minutes, 21.8 collected and obtain component fr.56 0.10g in～26.5 minutes, 26.5 collected and obtain component fr.57 0.2g in～30.3 minutes, 30.3 collected and obtain component fr.58 0.09g in～35.5 minutes, collection in 35.5～45 minutes obtains component fr.59 0.07g.
The fr.8 separation condition: chromatographic column is semi-preparative column (the Lichrospher C18 of Chinese nation; 10.0mm * 250mm, 5 μ m), mobile phase is water (A) and acetonitrile (B), and flow velocity is 3ml/min, and column temperature is a room temperature.The gradient elution program is as follows:
In the time of 0 minute, mobile phase A is that 90% aqueous solution, Mobile phase B are 10% acetonitrile solution;
In the time of 8 minutes, mobile phase A is that 81% aqueous solution, Mobile phase B are 19% acetonitrile solution;
In the time of 60 minutes, mobile phase A is that 65% aqueous solution, Mobile phase B are 35% acetonitrile solution;
In the time of 70 minutes, mobile phase A is that 95% aqueous solution, Mobile phase B are 5% acetonitrile solution.
Fr.8 separating resulting: get fr.82.6g, dissolve with methanol sample introduction with 20%, the component and the corresponding acquisition time that are obtained by the preparative liquid chromatography separation are as follows: collection in 4.0～7.7 minutes obtains component fr.81 0.05g, 7.7 collected and obtain component fr.82 0.12g in～10.7 minutes, 10.7 collected and obtain component fr.83 0.18g in～15.8 minutes, 15.8 collected and obtain component fr.840.28g in～18.8 minutes, 18.8 collected and obtain component fr.85 0.18g in～23.2 minutes, 23.2 collected and obtain component fr.86 0.23g in～27.4 minutes, 27.4 collected and obtain component fr.87 0.18g in～33.1 minutes, 33.1 collected and obtain component fr.88 0.16g in～40.2 minutes, 40.2 collected and obtain component fr.89 0.1g in～44.4 minutes, 44.4 collected and obtain component fr.810 0.12g in～48.5 minutes, 48.5 collected and obtain component fr.811 0.17g in～58 minutes, collected in 58～67 minutes and obtain component fr.812 0.06g, collection in 67～75 minutes obtains component fr.8130.15g.
Among the present invention, contained chemical compound sees Table 1 in each component of Cortex Moutan, and its Analysis and Identification method is referring to embodiment three.
Contained chemical compound in each component of table 1. Cortex Moutan
| Tree-peony root bark component | Compounds identified |
| fr.51 fr.52 fr.53 fr.54 fr.55 fr.56 fr.81 fr.82 fr.83 fr.84 fr.85 fr.86 fr.87 fr.88 fr.89 fr.810 fr.811 fr.812 | Paeoniflorin, Gallic Acid; Paeoniflorin, Gallic Acid; Paeoniflorin; Galloyl-Paeoniflorin, Mudanpioside h, Paeoniflorin; Mudanpioside c, Benzoyloxypaeoniflorin; Benzoylpaeoniflorin; Paeonidanin, Mudanoside b; Paeonidanin, Mudanoside b; Oxypaeoniflorin; Oxypaeoniflorin; Paeoniflorin; 1,2,3,6-tetra-O-galloyl-β-D-glucose, Suffruticoside a or Suffruticoside b or Suffruticoside c or Suffruticoside d; Galloyl-Paeoniflorin; Digalloyl-1,2,3,4-tetra-O-galloyl--D-glucopyranose; 1,2,3,4,6-Pentagalloylglucose, Digalloyl-1,2,3,4-tetra-O-galloyl--D-glucopyranose Mudanpioside c, Benzoyloxypaeoniflorin; Benzoyloxypaeoniflorin; Benzoylpaeoniflorin; |
Above Cortex Moutan extracts solution can be increased or reduce when industrialization is extracted according to corresponding ratio, as large-scale production can be unit with kilogram or with the ton, small-scale production can be unit with the gram also, and weight can increase or reduce, but its weight proportion constant rate.
The standardization extraction separation method that the present invention set up goes for the most of Chinese crude drug in the present Chinese medicine, for example can be used for Resina Ferulae, Folium Artemisiae Argyi, Benzoinum, Semen Platycladi, Carapax Trionycis, Semen Arecae, Herba Menthae, Semen Ricini, holds, Fructus Psoraleae, Radix Isatidis, Fructus Piperis Longi, Fructus Crotonis, Radix Morindae Officinalis, Rhizoma Menispermi, Radix Glehniae, Pseudobulbus Bletillae (Rhizoma Bletillae), the Radix Pulsatillae, the Radix Paeoniae Alba, the Radix Angelicae Dahuricae, Rhizoma Typhonii, Rhizoma Imperatae, Semen Ginkgo, Rhizoma Cynanchi Stauntonii, Semen Lablab Album, Radix Ampelopsis, Cortex Dictamni, Radix Cynanchi Atrati, Herba Lobeliae Chinensis, Herba Scutellariae Barbatae, the Rhizoma Pinelliae, Bulbus Lilii, Borneolum Syntheticum, Radix Bupleuri, Periostracum Cicadae, Fructus Broussonetiae, Radix Dichroae, Cortex Ailanthi, Squama Manis, Herba Andrographis, Semen Phaseoli, Halloysitum Rubrum, Radix Paeoniae Rubra, Rhizoma Atractylodis, Fructus Xanthii, Lignum Aquilariae Resinatum, Herba Sedi, Cacumen Platycladi, Radix Aconiti Kusnezoffii, Folium Aconiti Kusnezoffii, Semen Alpiniae Katsumadai, Fructus Tsaoko, Bulbus Fritillariae Cirrhosae, Radix Cyathulae, Radix Aconiti, Rhizoma Chuanxiong, Fructus Toosendan, Semen Plantaginis, Semen Sojae Preparatum, Radix Codonopsis, Herba Lophatheri, the Cortex Eucommiae, Radix Angelicae Pubescentis, Arisaema Cum Bile, Radix Cirsii Japonici, Pericarpium Arecae, Radix Salviae Miltiorrhizae, Gypsum Fibrosum Preparatum, Exocarpium Benincasae, Cordyceps, Pheretima, the Fructus Kochiae, Cortex Lycii, Radix Rehmanniae Preparata, Herba Euphorbiae Humifusae, Radix Sanguisorbae, Radix Angelicae Sinensis, Medulla Junci, Flos Caryophylli, Semen Canavaliae, Folium Isatidis, Fructus Jujubae, Radix Et Rhizoma Rhei, Herba Centipedae, Rhizoma Curcumae, catechu, Semen Torreyae, Herba Spirodelae, Rhizoma Dioscoreae Septemlobae, Fructus Rubi, Fructus Citri Sarcodactylis, Radix Aconiti Lateralis Preparata, Poria, Radix Stephaniae Tetrandrae, Radix Saposhnikoviae, Folium Sennae, Mel, Gecko, Ramulus Cinnamomi, Radix Puerariae, Rhizoma Ligustici, Rhizoma Alpiniae Officinarum, Rhizoma Drynariae, Fructus Setariae Germinatus, Flos Eriocauli, Rhizoma Cibotii, Fructus Lycii, Folium Ilicis Cornutae, Ramulus Uncariae Cum Uncis, Radix Et Rhizoma Nardostachyos, Radix Glycyrrhizae, Radix Kansui, Fructus Trichosanthis, Semen Trichosanthis, Pericarpium Trichosanthis, Caulis Aristolochiae Manshuriensis, Rhizoma Zingiberis, Rhizoma Zingiberis Preparatum, Resina Toxicodendri, Fructus Carpesii, the Radix Astragali, Rhizoma Polygonati, Sargassum, Flos Sophorae, Caulis Piperis Kadsurae, Folium Nelumbinis, Radix Scutellariae, Rhizoma Coptidis, Cortex Phellodendri, Pericarpium Zanthoxyli, Radix Polygoni Multiflori, Rhizoma Polygoni Cuspidati, Rhizoma Picrorhizae, Cortex Magnoliae Officinalis, Exocarpium Citri Grandis, Fructus Cannabis, Cortex Albiziae, Flos Albiziae, Radix Knoxiae, Flos Carthami, Semen Sesami Nigrum, Flos Chrysanthemi, Bombyx Batryticatus, Radix Platycodonis, Semen Citri Reticulatae, Rhizoma Curcumae Longae, Caulis Spatholobi, Flos Celosiae Cristatae, Radix Tinosporae, Herba Inulae, Rhizoma Fagopyri Dibotryis, Herba Lysimachiae, Flos Lonicerae, Lignum Dalbergiae Odoriferae, Herba Schizonepetae, Semen Allii Tuberosi, Semen Cassiae, Flos Farfarae, the Fructus Chebulae, Semen Armeniacae Amarum, Radix Sophorae Flavescentis, Cortex Meliae, Semen Raphani, Omphalia, Flos Campsis, Herba Pyrolae, Radix Rhapontici, Fructus Liquidambaris, Semen Nelumbinis, Caulis Trachelospermi, Aloe, Rhizoma Phragmitis, Rhizoma Anemones Raddeanae, Radix Zanthoxyli, Fructus Forsythiae, Ganoderma, Folium Apocyni Veneti, Fructus Momordicae, Semen Litchi, Radix Gentianae, Arillus Longan, Herba Erodii, Herba Ecliptae, Herba Ephedrae, Fructus Viticis, Folium Rhododendri Daurici, Oleum Rhododendri Daurici, Flos Buddlejae, Flos Mume, Herba Ephedrae, Radix Ophiopogonis, Fructus Hordei Germinatus, Flos Rosae Rugosae, Radix Changii, Herba Verbenae, Fructus Aristolochiae, Semen Strychni, Semen Strychni Pulveratum, Lasiosphaera Seu Calvatia, Herba Portulacae, Fructus Chaenomelis, the Radix Aucklandiae, the Herba Equiseti Hiemalis, Radix Adenophorae, Fructus Ligustri Lucidi, Fructus Arctii, Radix Achyranthis Bidentatae, Nodus Nelumbinis Rhizomatis, Pollen Typhae, Herba Taraxaci, Folium Eriobotryae, Herba Eupatorii, Rhizoma Wenyujin Concisum, Herba Dianthi, Cortex Fraxini, Rhizoma Bistortae, Semen Euryales, Rhizoma Et Radix Notopterygii, Radix Aristolochiae, Caulis Sinomenii, Pericarpium Citri Reticulatae Viride, Semen Celosiae, Herba Artemisiae Annuae, Indigo Naturalis, Radix Rubiae, Semen Pharbitidis, Radix Peucedani, Rhizoma Homalomenae, Semen Euphorbiae, Radix Gentianae Macrophyllae, Nux Prinsepiae, Semen Myristicae, Herba Cistanches, Cortex Cinnamomi, Radix Ginseng, Folium Ginseng, Rhizoma Acori Graminei, Herba Cynomorii, Folium Mori, Radix Phytolaccae, Fructus Mori, Fructus Cnidii, Cortex Mori, Ramulus Mori, Ramulus Mori, Herba Taxilli, Semen Aesculi, Semen Ziziphi Spinosae, Rhizoma Belamcandae, Styrax, Semen Astragali Complanati, Fructus Quisqualis, Calyx Kaki, Fructus Amomi, Radix Sophorae Tonkinensis, Fructus Corni, Rhizoma Dioscoreae, Pseudobulbus Cremastrae Seu Pleiones, Fructus Crataegi, Herba Cirsii, Rhizoma Cimicifugae, Cornu Bubali, Pulvis Cornus Bubali Concentratus, Folium Pyrrosiae, Concha Haliotidis, Herba Dendrobii, Pericarpium Granati, Rhizoma Zingiberis Recens, Retinervus Luffae Fructus, Radix Notoginseng, rhizoma sparganic, Semen Lepidii (Semen Descurainiae), Semen Cuscutae, Semen Persicae, Medulla Tetrapanacis, Lignum Santali Albi, Radix Trichosanthis, Concretio Silicea Bambusae, Rhizoma Arisaematis, Rhizoma Gastrodiae, Radix Semiaquilegiae, Radix Pseudostellariae, Cortex Pseudolaricis, Rhizoma Smilacis Glabrae, Fructus Evodiae, Radix Clematidis, Semen Vaccariae, Cortex Acanthopancis, Fructus Schisandrae Chinensis, Galla Chinensis, Concha Arcae, the Radix Linderae, Fructus Mume, Rhizoma Corydalis Decumbentis, Radix Dipsaci, Flos Inulae Herba Siegesbeckiae, Bulbus Allii Macrostemonis, Spica Prunellae, Flos Magnoliae, Cortex Periplocae, Rhizoma Cyperi, Fructus Citri, Herba Moslae, Fructus Foeniculi, Rhizoma Curculiginis, Herba Agrimoniae, Radix Scrophulariae, Matrii Sulfas Exsiccatus, Radix Panacis Quinquefolii, Crinis Carbonisatus, Sanguis Draxonis, Radix Cynanchi Paniculati, Herba Epimedii, Herba Leonuri, Folium Ginkgo, Semen Coicis, Radix Stellariae, Radix Polygalae, Flos Genkwa, Semen Pruni, Radix Curcumae, Herba Houttuyniae, Herba Artemisiae Scopariae, Fructus Bruceae, Flos Rosae Chinensis, Rhizoma Polygonati Odorati, Rhizoma Corydalis, Bulbus Fritillariae Thunbergii, Fructus Gleditsiae Abnormalis, Fructus Perillae, Radix Asteris, Herba Violae, Radix Arnebiae (Radix Lithospermi), Polyporus, Spina Gleditsiae, the Rhizoma Anemarrhenae, the Herba Lycopi, Rhizoma Alismatis, Concha Margaritifera, Fructus Aurantii Immaturus, Fructus Gardeniae.
Any form on the pharmaceutics be can make according to the Cortex Moutan effective ingredient that the inventive method obtained, injection and oral formulations comprised.Wherein injection comprises injection, drip liquid, injectable powder; Oral formulations comprises granule, tablet, electuary, powder, oral liquid, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, sucks agent, granule, pill, unguentum, sublimed preparation, spray, drop pill, disintegrating agent, oral cavity disintegration tablet, micropill etc.
To those skilled in the art, technology contents disclosed according to the present invention, those skilled in the art will very clear other embodiment of the present invention, and the embodiment of the invention is only as example.Under the situation of not violating purport of the present invention and scope; can carry out various changes and improvements to the present invention; for example selected solution can be other lower alcohols or other organic solvents, but as long as use extracting method of the present invention, all within protection domain of the present invention.
Description of drawings
Provide the Cortex Moutan finger printing below, each component ultraviolet spectrogram of Cortex Moutan water solublity, each component mass spectrum of Cortex Moutan water solublity, fat-soluble each the component ultraviolet spectrogram of Cortex Moutan, fat-soluble each the component mass spectrum of Cortex Moutan are intended to further specify the present invention, but the present invention are not construed as limiting.
Fig. 1 Cortex Moutan finger printing
Each component uv-spectrogram of Fig. 2 Cortex Moutan water solublity
Each component mass spectrum of Fig. 3 Cortex Moutan water solublity
Fat-soluble each the component uv-spectrogram of Fig. 4 Cortex Moutan
Fat-soluble each the component mass spectrum of Fig. 5 Cortex Moutan
The specific embodiment
Embodiment one
The extraction of Cortex Moutan with separate
(1) extraction process: take by weighing 250g Cortex Moutan medical material, with its grinding and sieving, add ethyl acetate and ethanol then, heating extraction gets extracting solution fr.1.Add ethanol in medicinal residues, heating extraction gets extracting solution fr.2.Add entry in medicinal residues at last, heating extraction gets extracting solution fr.3.
(2) separating technology: with extracting solution fr.1 concentrate 20g extractum, use silica gel mixed sample, adopt normal phase silicagel column that it is separated, at first use petroleum ether and ethyl acetate as mobile phase, get eluent fr.4, change chloroform and methanol then as mobile phase, get eluent fr.5, concentrate the 5.9g sample, use methanol as mobile phase at last, eluent fr.6.With extracting solution fr.2 concentrate 51g extractum, with sample on the dissolve with methanol, adopt the ODS-C18 post that it is separated, the methanol of at first using low concentration gets eluent fr.7 as mobile phase, and the methanol that changes intermediate concentration then is as mobile phase, get eluent fr.8, concentrate the 2.2g sample, use pure methanol solution as mobile phase at last, eluent fr.9.
(3) preparation separating technology: continue to separate fr.5 and the fr.8 that obtains in the previous process with preparative liquid chromatography.Chromatographic column is semi-preparative column (Lichrospher C18; 10.0mm * 250mm, 5 μ m), mobile phase is water and acetonitrile, gradient elution is collected fraction in the corresponding time period, obtains to have passed through further isolating each component.
Fr.5 separating resulting: get component fr.5 1.5g, dissolve with ethanol sample introduction with 10%, the component and the corresponding acquisition time that are obtained by the preparative liquid chromatography separation are as follows: collection in 4.0～7.6 minutes obtains component fr.51 0.11g, 7.6 collected and obtain component fr.52 0.09g in～9.7 minutes, 9.7 collected and obtain component fr.53 0.29g in～14.2 minutes, 14.2 collected and obtain component fr.540.11g in～18.4 minutes, 21.8 collected and obtain component fr.55 0.19g in～26.5 minutes, 21.8 collected and obtain component fr.56 0.09g in～26.5 minutes, 26.5 collected and obtain component fr.57 0.2g in～30.3 minutes, 30.3 collected and obtain component fr.58 0.08g in～35.5 minutes, collection in 35.5～45 minutes obtains component fr.59 0.05g.
Fr.8 separating resulting: get fr.8 2.5g, dissolve with methanol sample introduction with 20%, the component and the corresponding acquisition time that are obtained by the preparative liquid chromatography separation are as follows: collection in 4.0～7.7 minutes obtains component fr.81 0.04g, 7.7 collected and obtain component fr.82 0.10g in～10.7 minutes, 10.7 collected and obtain component fr.83 0.16g in～15.8 minutes, 15.8 collected and obtain component fr.840.26g in～18.8 minutes, 18.8 collected and obtain component fr.85 0.17g in～23.2 minutes, 23.2 collected and obtain component fr.86 0.21g in～27.4 minutes, 27.4 collected and obtain component fr.87 0.15g in～33.1 minutes, 33.1 collected and obtain component fr.88 0.12g in～40.2 minutes, 40.2 collected and obtain component fr.89 0.09g in～44.4 minutes, 44.4 collected and obtain component fr.810 0.11g in～48.5 minutes, 48.5 collected and obtain component fr.811 0.13g in～58 minutes, collected in 58～67 minutes and obtain component fr.812 0.04g, collection in 67～75 minutes obtains component fr.813 0.12g.
Embodiment two
The extraction of Cortex Moutan with separate
(1) extraction process: take by weighing 500g Cortex Moutan medical material, with its grinding and sieving, adding 5～12 times of amount volume ratios then is 1: 1 ethyl acetate and ethanol, and reflux 0.5～3 hour is extracted 1～3 time, and merging filtrate gets extracting solution fr.1.Add 5～12 times of amount 70% ethanol in medicinal residues, reflux 0.5～3 hour is extracted 1～3 time, and merging filtrate gets extracting solution fr.2.Add entry in medicinal residues at last, reflux 0.5～3 hour is extracted 1～3 time, and merging filtrate gets extracting solution fr.3.
(2) separating technology: with extracting solution fr.1 concentrate 41g extractum, use silica gel mixed sample, adopt normal phase silicagel column that it is separated, at first with volume ratio be 50: 1 petroleum ether and ethyl acetate as mobile phase, eluent fr.4, change volume ratio then and be 10: 1 chloroform and methanol as mobile phase, get eluent fr.5, concentrate the 11.8g sample, use methanol as mobile phase at last, eluent fr.6.With extracting solution fr.2 concentrate 108g extractum, with sample on 2～10% dissolve with methanol, adopt the ODS-C18 post that it is separated, at first use 2～10% methanol as mobile phase, get eluent fr.7, change 40～80% methanol then as mobile phase, get eluent fr.8, concentrate the 4.8g sample, use 100% methanol solution as mobile phase at last, eluent fr.9.
(3) preparation separating technology: continue to separate fr.5 and the fr.8 that obtains in the previous process with preparative liquid chromatography.Chromatographic column is semi-preparative column (Lichrospher C18; 10.0mm * 250mm, 5 μ m), mobile phase is water and acetonitrile, and gradient elution, flow velocity are 3ml/min, and column temperature is a room temperature, collects fraction in the corresponding time period, obtains through further isolating each component.
Fr.5 separating resulting: get component fr.53g, dissolve with ethanol sample introduction with 10%, the component and the corresponding acquisition time that are obtained by the preparative liquid chromatography separation are as follows: collection in 4.0～7.6 minutes obtains component fr.51 0.29g, 7.6 collected and obtain component fr.52 0.21g in～9.7 minutes, 9.7 collected and obtain component fr.53 0.62g in～14.2 minutes, 14.2 collected and obtain component fr.540.23g in～18.4 minutes, 21.8 collected and obtain component fr.55 0.4g in～26.5 minutes, 21.8 collected and obtain component fr.56 0.17g in～26.5 minutes, 26.5 collected and obtain component fr.57 0.37g in～30.3 minutes, 30.3 collected and obtain component fr.58 0.17g in～35.5 minutes, collection in 35.5～45 minutes obtains component fr.59 0.12g.
Fr.8 separating resulting: get fr.85g, dissolve with methanol sample introduction with 20%, the component and the corresponding acquisition time that are obtained by the preparative liquid chromatography separation are as follows: collection in 4.0～7.7 minutes obtains component fr.81 0.09g, 7.7 collected and obtain component fr.82 0.22g in～10.7 minutes, 10.7 collected and obtain component fr.83 0.33g in～15.8 minutes, 15.8 collected and obtain component fr.840.53g in～18.8 minutes, 18.8 collected and obtain component fr.85 0.31g in～23.2 minutes, 23.2 collected and obtain component fr.86 0.42g in～27.4 minutes, 27.4 collected and obtain component fr.87 0.31g in～33.1 minutes, 33.1 collected and obtain component fr.88 0.31g in～40.2 minutes, 40.2 collected and obtain component fr.89 0.17g in～44.4 minutes, 44.4 collected and obtain component fr.810 0.22g in～48.5 minutes, 48.5 collected and obtain component fr.811 0.32g in～58 minutes, collected in 58～67 minutes and obtain component ff.812 0.1g, collection in 67～75 minutes obtains component fr.8130.28g.
Embodiment three
One. the extraction of Cortex Moutan with separate
Accurately take by weighing Cortex Moutan medical material 250g, with its grinding and sieving, adding 8 times of amount volume ratios then is 1: 1 ethyl acetate and ethanol, and reflux 1 hour is extracted 2 times, and merging filtrate gets extracting solution fr.1.Add 8 times of amount 70% ethanol in medicinal residues, reflux 1 hour is extracted 2 times, and merging filtrate gets extracting solution fr.2.Add entry in medicinal residues at last, reflux 1 hour is extracted 2 times, and merging filtrate gets extracting solution fr.3.
With extracting solution fr.1 concentrate 22g extractum, use silica gel mixed sample, adopt normal phase silicagel column that it is separated, at first with volume ratio be 50: 1 petroleum ether and ethyl acetate as mobile phase, eluent fr.4, change volume ratio then and be 10: 1 chloroform and methanol as mobile phase, get eluent fr.5, concentrate the 6.2g sample, use methanol as mobile phase at last, eluent fr.6.With extracting solution fr.2 concentrate 55g extractum, with sample on 5% dissolve with methanol, adopt the ODS-C18 post that it is separated, at first use 5% methanol as mobile phase, get eluent fr.7, change 60% methanol then as mobile phase, get eluent fr.8, concentrate the 2.6g sample, use 100% methanol solution as mobile phase at last, eluent fr.9.
Continue to separate fr.5 and fr.8 with preparative liquid chromatography.
The fr.5 separation condition: chromatographic column is semi-preparative column (the Lichrospher C18 of Chinese nation; 10.0mm * 250mm, 5 μ m), mobile phase is water (A) and acetonitrile (B), and flow velocity is 3ml/min, and column temperature is a room temperature.The gradient elution program is as follows:
In the time of 0 minute, mobile phase A is that 80% aqueous solution, Mobile phase B are 20% acetonitrile solution;
In the time of 40 minutes, mobile phase A is that 20% aqueous solution, Mobile phase B are 80% acetonitrile solution;
In the time of 50 minutes, mobile phase A is that 5% aqueous solution, Mobile phase B are 95% acetonitrile solution.
Fr.5 separating resulting: get component fr.5 1.4g, dissolve with ethanol sample introduction with 10%, the component and the corresponding acquisition time that are obtained by the preparative liquid chromatography separation are as follows: collection in 4.0～7.6 minutes obtains component fr.51 0.16g, 7.6 collected and obtain component fr.52 0.11g in～9.7 minutes, 9.7 collected and obtain component fr.53 0.32g in～14.2 minutes, 14.2 collected and obtain component fr.540.13g in～18.4 minutes, 21.8 collected and obtain component fr.55 0.21g in～26.5 minutes, 21.8 collected and obtain component fr.56 0.10g in～26.5 minutes, 26.5 collected and obtain component fr.57 0.2g in～30.3 minutes, 30.3 collected and obtain component fr.58 0.09g in～35.5 minutes, collection in 35.5～45 minutes obtains component fr.59 0.07g.
The fr.8 separation condition: chromatographic column is semi-preparative column (the Lichrospher C18 of Chinese nation; 10.0mm * 250mm, 5 μ m), mobile phase is water (A) and acetonitrile (B), and flow velocity is 3ml/min, and column temperature is a room temperature.The gradient elution program is as follows:
In the time of 0 minute, mobile phase A is that 90% aqueous solution, Mobile phase B are 10% acetonitrile solution;
In the time of 8 minutes, mobile phase A is that 81% aqueous solution, Mobile phase B are 19% acetonitrile solution;
In the time of 60 minutes, mobile phase A is that 65% aqueous solution, Mobile phase B are 35% acetonitrile solution;
In the time of 70 minutes, mobile phase A is that 95% aqueous solution, Mobile phase B are 5% acetonitrile solution.
Fr.8 separating resulting: get fr.8 2.6g, dissolve with methanol sample introduction with 20%, the component and the corresponding acquisition time that are obtained by the preparative liquid chromatography separation are as follows: collection in 4.0～7.7 minutes obtains component fr.81 0.05g, 7.7 collected and obtain component fr.82 0.12g in～10.7 minutes, 10.7 collected and obtain component fr.83 0.18g in～15.8 minutes, 15.8 collected and obtain component fr.840.28g in～18.8 minutes, 18.8 collected and obtain component fr.85 0.18g in～23.2 minutes, 23.2 collected and obtain component fr.86 0.23g in～27.4 minutes, 27.4 collected and obtain component fr.87 0.18g in～33.1 minutes, 33.1 collected and obtain component fr.88 0.16g in～40.2 minutes, 40.2 collected and obtain component fr.89 0.1g in～44.4 minutes, 44.4 collected and obtain component fr.810 0.12g in～48.5 minutes, 48.5 collected and obtain component fr.811 0.17g in～58 minutes, collected in 58～67 minutes and obtain component fr.812 0.06g, collection in 67～75 minutes obtains component fr.8130.15g.
Two. analyze
2.1 instrument and reagent
Agilent 1100 high performance liquid chromatography-GC-MS (U.S. Agilent company) fit over line vacuum degasser, quarternary low pressure pump, automatic sampler, column oven, DAD detector, 1946D electron spray level Four bar mass detector, Chemstation chromatographic work station; R-200 type Rotary Evaporators (Switzerland BUCHI company); Flying pigeon board TGL-16G high speed tabletop centrifuge (Anting Scientific Instrument Factory, Shanghai); METTLER-AE240 type electronic balance (prunus mume (sieb.) sieb.et zucc. Teller-Tuo benefit Instr Ltd.).
Acetonitrile is chromatographically pure reagent (Merck), and water is WAHAHA pure water (Hangzhou WAHAHA group).
2.2 analytical method
Sample source: tree-peony root bark component fr.51 1.75mg, fr.52 1.76mg, fr.53 1.78mg, fr.54 1.74mg, fr.551.69mg, fr.56 1.72mg, fr.57 1.84mg, fr.58 1.88mg, fr.59 1.22mg.
Sample preparation: sample is used the 1ml dissolve with ethanol respectively, and is ultrasonic, and centrifugal (10000r/min) is standby.
Chromatographic condition: chromatographic column Agilent Zorbax SB-C18 post (4.6mm * 150mm, 5 μ m); Adopt gradient elution, mobile phase A is 0.2% glacial acetic acid aqueous solution mutually, and Mobile phase B is mutually for containing the acetonitrile solution of 0.2% glacial acetic acid; The gradient elution program is as follows: in the time of 0 minute, mobile phase A is that 90% 0.2% glacial acetic acid aqueous solution, Mobile phase B are 10% 0.2% glacial acetic acid acetonitrile solution; In the time of 10 minutes, mobile phase A is that 50% 0.2% glacial acetic acid aqueous solution, Mobile phase B are 50% 0.2% glacial acetic acid acetonitrile solution; In the time of 30 minutes, mobile phase A is that 5% 0.2% glacial acetic acid aqueous solution, Mobile phase B are 95% 0.2% glacial acetic acid acetonitrile solution; In the time of 35 minutes, mobile phase A is that 5% 0.2% glacial acetic acid aqueous solution, Mobile phase B are 95% 0.2% glacial acetic acid acetonitrile solution.Flow velocity 0.5mL/min; It is long to detect the wavelength all-wave; 30 ℃ of column temperatures; Sample size is 5 μ l.
Mass spectrum condition: negative ions scan pattern, sweep limits 100～2000; Dry gas (N
2Stream speed 10L/min, 350 ℃ of atomization temperatures, capillary voltage 3500V, cracking voltage 100V.
Sample source: tree-peony root bark component fr.81 1.88mg, fr.82 1.83mg, fr.83 1.90mg, fr.84 1.86mg, fr.851.88mg, fr.86 1.78mg, fr.87 1.85mg, fr.88 1.88mg, fr.89 1.81mg, ff.810 1.75mg, fr.8111.79mg, fr.812 1.94mg.
Sample preparation: sample is with the dissolving of 1ml 50% methanol-water, and is ultrasonic, and centrifugal (10000r/min) is standby.
Chromatographic condition: chromatographic column Agilent Zorbax SB-C
18Post (4.6mm * 150mm, 5 μ m); Adopt gradient elution, mobile phase A is 0.2% glacial acetic acid aqueous solution mutually, and Mobile phase B is mutually for containing the acetonitrile solution of 0.2% glacial acetic acid; The gradient elution program is as follows: in the time of 0 minute, mobile phase A is that 90% 0.2% glacial acetic acid aqueous solution, Mobile phase B are 10% 0.2% glacial acetic acid acetonitrile solution; In the time of 20 minutes, mobile phase A is that 70% 0.2% glacial acetic acid aqueous solution, Mobile phase B are 30% 0.2% glacial acetic acid acetonitrile solution; In the time of 30 minutes, mobile phase A is that 50% 0.2% glacial acetic acid aqueous solution, Mobile phase B are 50% 0.2% glacial acetic acid acetonitrile solution; In the time of 35 minutes, mobile phase A is that 50% 0.2% glacial acetic acid aqueous solution, Mobile phase B are 50% 0.2% glacial acetic acid acetonitrile solution.Flow velocity 0.5mL/min; It is long to detect the wavelength all-wave; 30 ℃ of column temperatures; Sample size is 5 μ l.
Mass spectrum condition: negative ions scan pattern, sweep limits 100～2000; Dry gas (N
2Stream speed 10L/min, 350 ℃ of atomization temperatures, capillary voltage 3500V, cracking voltage 100V.
2.3 analysis result
Analysis result: Fig. 2 is each component uv-spectrogram of Cortex Moutan water solublity, and Fig. 3 is each component mass spectrum of Cortex Moutan water solublity, and Fig. 4 is fat-soluble each the component uv-spectrogram of Cortex Moutan, and Fig. 5 is fat-soluble each the component mass spectrum of Cortex Moutan.
The qualification result of chemical compound in the tree-peony root bark component
[1-12]See Table 2.
Table 2. tree-peony root bark component compound identification result
| Tree-peony root bark component | Chromatographic retention (min) | [M-H]- | Ultraviolet maximum absorption wavelength (nm) | Chemical compound |
| fr.51 | 5.01 | 169 | 215，280 | Gallic Acid (gallic acid) [1] |
| 9.5 | 479 | 230 | Paeoniflorin (peoniflorin) [1] | |
| fr.52 | 5.01 | 169 | 215，280 | Gallic Acid (gallic acid) [1] |
| 9.5 | 479 | 230 | Paeoniflorin (peoniflorin) [1] | |
| fr.53 | 9.5 | 479 | 230 | Paeoniflorin (peoniflorin) [1] |
| fr.54 | 9.5 | 479 | 230 | Paeoniflorin (peoniflorin) [1] |
| 10.8 | 631 | 215，280 | Galloyl-Paeoniflorin (gallic acid peoniflorin) [2] | |
| 11.6 | 615 | 215，280 | Mudanpioside h (paeonoside h) [3] | |
| fr.55 | 12.0 | 599 | 230 | Mudanpioside c (paeonoside c) [4] |
| 12.3 | 599 | 230 | Benzoyloxypaeoniflorin (Benzoyloxypaeoniflorin) [4] [5] | |
| fr.56 | 13.5 | 583 | 230 | Benzoylpaeoniflorin (benzoylpaeoniflorin) [1] [4] [6] [7] [8] |
| fr.81 | 4.4 | 493 | 215，280 | Unknown |
| 4.6 | 463 | 215，280 | Mudanoside b (paeonoside b) [4] | |
| fr.82 | 4.3 | 493 | 215，280 | Paeonidanin[9] |
| 4.4 | 493 | 215，280 | Unknown | |
| 4.6 | 463 | 215，275 | Mudanoside b (paeonoside b) [4] | |
| fr.83 | 9.8 | 494 | 254 | Oxypaeoniflorin (Hydroxy peoniflorin) [4] [10] [11] |
| fr.84 | 9.8 | 494 | 254 | Oxypaeoniflorin (Hydroxy peoniflorin) [4] [10] [11] |
| fr.85 | 14.8 | 479 | 230 | Paeoniflorin (peoniflorin) [1] |
| fr.86 | 15.7 | 787 | 215，280 | 1,2,3,6-tretra-O-gaLloly-β-D-glucose (four gallic acid glucoses) [12] |
| 16.3 | 787 | 215，280 | 1,2,3,6-tretra-O-gaLloly-β-D-glucose (four gallic acid glucoses) [12] | |
| 17.1 | 611 | 215，280 | Suffruticoside A or Suffruticoside B or Suffruticoside C or Suffruticoside D[2] | |
| fr.87 | 18.3 | 939 | 215，280 | 1,2,3,4,6-Pentagalloylglucose (five gallic acid peoniflorins) [12] |
| fr.88 | 20.1 | 1091 | 215，280 | Digalloyl-1,2,3,4-tetra-O-galloyl--D-glucopyranose six gallic acid peoniflorins [12] |
| 21.0 | 1091 | 215，280 | Digalloyl-1,2,3,4-tetra-O-galloyl--D-glucopyranose (six gallic acid peoniflorins) [12] | |
| fr.89 | 18.3 | 939 | 215，275 | 1,2,3,4,6-Pentagalloylglucose (five gallic acid peoniflorins) [12] |
| 21.0 | 1091 | 215，280 | Digalloyl-1,2,3,4-tetra-O-galloyl--D-glucopyranose (six gallic acid peoniflorins) [12] | |
| fr.810 | 25.2 | 599 | 230 | Mudanpioside c (paeonoside c) [4] |
| 26.1 | 599 | 230 | Benzoyloxypaeoniflorin (Benzoyloxypaeoniflorin) [4] [5] | |
| fr.811 | 26.1 | 599 | 230 | Benzoyloxypaeoniflorin (Benzoyloxypaeoniflorin) [4] [5] |
| fr.812 | 29.7 | 583 | 230 | Benzoylpaeoniflorin (benzoylpaeoniflorin) [1] [4] [6] [7] [8] |
List of references:
[1]Ishida H.，Takamatsu M.，Tsuji K.，Kosuge T.，Chem.Pharm.Bull.，1987，35(2)，849-852。
[2]Yoshikawa M.，Uchida E.，Kawaguchi A.，Kitagawa I.，Yamahara，J.Chem.Pharm.Bull.，1992，40(8)，2248-2250。
[3]Ding H.Y.，Wu Y.C.，Lin H.C.，Chan Y.Y.，Wu P.L.，Wu T.S.，Chem.Pharm.Bull.，1999，47(5)，652-655。
[4]Lin H.C.，Ding H.Y.，Wu T.S.，Wu P.L.，Wu T.S.，Phytochemistry，1996，41(1)，237-242。
[5]Kitagawa I.，Yoshikawa M.，Tsunaga K.，Tani T.，Shoyakugaku Zasshi，1979，33，171-177。
[6]Kosato H.，Arichi S.，Kubo M.，Matsuda H.，Kimura Y.，Kitagawa I.，Yoshikawa M.，Wakanyaku Shinpojium，1984，14，86。
[7]Takagi M.，Hadara M.，Yakugaku Zasshi，1969，89，879。
[8]Kubo M.，Matsuda H.，Izumi S.，Tani T.，Arichi S.，Yoshikawa M.，Kitagawa I.，ShoyakugakuZasshi，1982，36，70-77。
[9]Kostova I.N.，Simenov M.F.，Todorova D.I.，Phytochemistry，1998，47(2)，1303-1307。
[10]Chen H.S.，Liao S.x.，Hong Z.J.，Chin.Pharm.J.，1993，28，137-138。
[11]Kaneda M.，Iitaka M.，Shibata S.，Tstrahedron，1972，28，4309。
[12]Nishizawa M.，Yamagishi T.，Nonaka G.，Nishioka I.，Nagasawa T.，Oura H.，Chem.Pharm.Bull.，1983，31(8)，2593-2600。
Three, pharmacological evaluation
3.1 pharmacological model: neonatal rat myocardial cell hypoxic-ischemic model
After former generation, myocardial cell was cultivated birth SD neonatal rat execution in 1～3 day, it was dirty to core, and is cut into the fragment about 1mm3 after PBS liquid cleans.With 0.125% trypsin Sigma, USA)+0.05% (Gibco is USA) in 37 ℃ of digestion 3～4 times for collagenase II.The differential adherent method was separated into fibrocyte after 1.5 hours, and cell suspension is transferred to (about 4 * 105 cells in every hole) in 48 orifice plates.(Gibco, (Falcon, USA) cell of cultivating 3-6 days supplies medicine efficacy screening USA) to add 10% hyclone through DMEM.Screen and replaced with serum-free medium in preceding 1 day.Cultivate 3～6 days myocardial cell, PBS washing back adds the pastille culture fluid.Place 95%N
2And 5%CO
2Anoxia is 6 hours in the incubator.Then at CO
2Reoxygenation is 3 hours in the incubator.Get cell conditioned medium liquid and measure LDH content.
Dosage regimen is extracted the tree-peony root bark component that obtains and is made into 10 with sugar-free Hanks liquid
-4G/mL test liquid, liposoluble constituent can add a small amount of DMSO hydrotropy (the DMSO final concentration is controlled at below 0.2%).The final concentration of each component in culture fluid is controlled at 10
-5G/mL.
Lactic acid dehydrogenase content can be represented the cell injury degree in the lactic acid dehydrogenase assay cell culture fluid.The lactic acid dehydrogenase content that bleeds in the supernatant is high more, shows that cell injury is also remarkable.The determination of lactate dehydrogenase test kit builds up bio-engineering research institute available from Nanjing.Assay method is: get 30 μ l cell conditioned medium liquid, add 50 μ l substrate buffer and 10 μ l lactic dehydrogenase enzyme cofactors, 37 ℃ vibrated 15 minutes, added 50 μ l 2,4 dinitrophenyl hydrazines again, and 37 ℃ vibrated 15 minutes.Parallel blank.Extract reaction solution 50 μ l and add 200 μ l 0.4mol/L sodium hydroxide solutions, leave standstill 3～4 minutes after, measure shading value with microplate reader in 450nm.
Drug effect result
All data are represented with the mean value variance.Adopt monolateral variance analysis and T check carrying out statistical analysis.Compare with model group, P＜0.05 is thought significantly effectively.Medicine efficacy screening the results are shown in Table 3 and table 4.According to myocardial cell lactic acid dehydrogenase (LDH) The selection result, Cortex Moutan fr.51, fr.52, fr.53, fr.54, fr.56, fr.57, fr.58, fr.81, fr.83, fr.810 has the highly significant effect to reducing LDH release.
Table 3. myocardial cell The selection result
| Component | Mean | Std | P |
| Fr.51 fr.52 fr.53 fr.54 fr.55 fr.56 fr.57 fr.58 fr.59 fr.81 fr.82 model group | 0.1765 0.183 0.144 0.1355 0.189625 0.153 0.1795 0.191 0.21625 0.18925 0.22775 0.22575 | 0.01852 0.024522 0.023022 0.031522 0.034548 0.01472 0.015155 0.010132 0.028826 0.017988 0.011354 0.032887 | 0.020068 0.041129 0.003278 0.003716 0.090309 0.003408 0.021615 0.044976 0.339571 0.049707 0.456111 |
Table 4. myocardial cell screening structure
| Component | Mean | Std | P |
| Fr.83 fr.84 fr.85 fr.86 fr.87 fr.88 fr.89 fr.810 fr.811 fr.812 fr.813 model group | 0.055333 0.209667 0.220333 0.17875 0.234333 0.16775 0.28 0.006333 0.1955 0.182667 0.16825 0.152333 | 0.01222 0.009292 0.006028 0.029443 0.005686 0.022955 0.006557 0.003512 0.020857 0.028537 0.032694 0.01823 | 0.001453 0.006984 0.000749 0.116943 0.000821 0.192291 0.264608 0.024013 0.017962 0.387848 0.243806 |
3.2 huve cell anoxia reoxygenation model
The healthy newborn umbilical cord is got in former generation huve cell cultivation, cleans the interior residual bloodstain of vein blood vessel with 30～50mlHanks liquid.Look the 0.1% collagenase I that umbilical cord length adds respective amount, change incubator digestion 15～20 minutes over to.Subsequently Digestive system in the umbilical cord is carefully collected in the beaker, and with Hanks liquid with beaker rinse twice, collect in the lump and be sub-packed in centrifuge tube in the beaker, centrifugal 10 minutes of 900rpm.Supernatant is removed in suction, with the abundant dissolution precipitation of M199 culture fluid (contain 10% hyclone, 100U/ml is two anti-, 0.15mg/ml Heparin, 10 μ M VC).Gained cell suspension is sub-packed in 5cm
2Culture bottle places in the incubator and cultivates.Changed in second day and adopt the M199 culture fluid that contains 30 μ g/ml ECGS, changed a culture fluid and be paved with the bottom surface in per afterwards three days until cell.Used cell is former generation endotheliocyte.The culture bottle inner cell is seeded to 96 orifice plates before the modeling and cultivated one day, used cell concentration is 3.5～40,000/hole.During modeling, inhale and abandon old M199 culture fluid, adding pastille does not have phenol red M199 culture fluid, and every hole total amount is 100 μ l.Place 95%N
2And 5%CO
2Anoxia is 12 hours in the incubator, then at CO
2Reoxygenation is 2 hours in the incubator.Get cell conditioned medium liquid and measure LDH content and NO content.
Dosage regimen is extracted the tree-peony root bark component that obtains and is made into 10 with sugar-free Hanks liquid
-4G/mL test liquid, liposoluble constituent can add a small amount of DMSO hydrotropy (the DMSO final concentration is controlled at below 0.2%).The final concentration of each component in no phenol red M199 culture fluid is controlled at 10
-5G/mL.
Lactic acid dehydrogenase content can be represented the cell injury degree in the lactic acid dehydrogenase assay cell culture fluid.The lactic acid dehydrogenase content that bleeds in the supernatant is high more, shows that cell injury is also remarkable.The determination of lactate dehydrogenase test kit builds up bio-engineering research institute available from Nanjing.Assay method is: get 30 μ l cell conditioned medium liquid, add 50 μ l substrate buffer and 10 μ l lactic dehydrogenase enzyme cofactors, 37 ℃ vibrated 15 minutes, added 50 μ l 2,4 dinitrophenyl hydrazines again, and 37 ℃ vibrated 15 minutes.Parallel blank.Extract reaction solution 50 μ l and add 200 μ l 0.4mol/L sodium hydroxide solutions, leave standstill 3～4 minutes after, measure shading value with microplate reader in 450nm.
The NO assay adopts Greiss reagent method to measure, and gets 90 μ l cell conditioned medium liquid, adds equivalent Greiss reagent, leaves standstill under the room temperature 10 minutes, measures absorbance with microplate reader in 550nm.
Drug effect all data is as a result represented with the mean value variance.Adopt monolateral variance analysis and T check carrying out statistical analysis.Compare with model group, P＜0.05 is thought significantly effectively.Medicine efficacy screening the results are shown in Table 5 and table 6.According to endotheliocyte NO The selection result, Cortex Moutan fr.811 has the highly significant effect to improving NO release, and fr.56 has remarkable result.According to endotheliocyte LDH (lactic acid dehydrogenase) The selection result, Cortex Moutan fr.58 has the highly significant effect to reducing LDH release, and fr.52, fr.53, fr.54, fr.56, fr.57 have remarkable result.
Table 5. endotheliocyte NO The selection result
| Component | Mean | Std | P |
| Fr.56 fr.811 model group | 0.063 0.062 0.056 | 0.005 0.002 0.003 | 0.027 ** 0.007 *** |
Table 6. endotheliocyte LDH The selection result
| Component | Mean | Std | P |
| Fr.52 fr.53 fr.54 fr.56 fr.57 fr.58 model group | 0.101 0.110 0.104 0.107 0.110 0.108 0.122 | 0.014 0.011 0.016 0.015 0.012 0.005 0.006 | 0.015 ** 0.018 ** 0.049 ** 0.041 ** 0.033 ** 0.001 *** |
Above result of the test explanation, the Chinese crude drug effective ingredient that adopts Chinese crude drug standardization extracting method of the present invention to obtain can be as the preparation medicine.
Claims (5)
1. Cortex Moutan extraction, separation criterion method may further comprise the steps:
(1) extraction process: take by weighing the Cortex Moutan medical material, with its grinding and sieving, add ethyl acetate and ethanol then, heating extraction gets extracting solution fr.1; Add ethanol in medicinal residues, heating extraction gets extracting solution fr.2; Add entry in medicinal residues at last, heating extraction gets extracting solution fr.3;
(2) separating technology: after extracting solution fr.1 is condensed into extractum, use silica gel mixed sample, adopt normal phase silicagel column that it is separated, at first use petroleum ether and ethyl acetate as mobile phase, get eluent fr.4, change chloroform and methanol then, get eluent fr.5 as mobile phase, use methanol as mobile phase at last, get eluent fr.6; After extracting solution fr.2 is condensed into extractum, with sample on the dissolve with methanol, adopt the ODS-C18 post that it is separated, the methanol of at first using low concentration is as mobile phase, get eluent fr.7, the methanol that changes intermediate concentration then gets eluent fr.8 as mobile phase, use pure methanol solution as mobile phase at last, get eluent fr.9;
(3) preparation separating technology: continue to separate fr.5 and fr.8 with preparative liquid chromatography; Chromatographic column is a semi-preparative column, and mobile phase is water and acetonitrile, and gradient elution is collected fraction in the corresponding time period, obtains through further isolating each component.
2. Cortex Moutan as claimed in claim 1 extracts, the separation criterion method, comprises the steps:
(1) extraction process: take by weighing the Cortex Moutan medical material, with its grinding and sieving, adding 5～12 times of amount volume ratios then is 1: 1 ethyl acetate and ethanol, and reflux 0.5～3 hour is extracted 1～3 time, and merging filtrate gets extracting solution fr.1; Add 5～12 times of amount 70% ethanol in medicinal residues, reflux 0.5～3 hour is extracted 1～3 time, and merging filtrate gets extracting solution fr.2; Add entry in medicinal residues at last, reflux 0.5～3 hour is extracted 1～3 time, and merging filtrate gets extracting solution fr.3;
(2) separating technology: after extracting solution fr.1 is condensed into extractum, use silica gel mixed sample, adopt normal phase silicagel column that it is separated, be that 50: 1 petroleum ether and ethyl acetate are as mobile phase at first with volume ratio, eluent fr.4, change volume ratio then and be 10: 1 chloroform and methanol as mobile phase, eluent fr.5, use methanol as mobile phase at last, get eluent fr.6; After extracting solution fr.2 is condensed into extractum, with sample on 2～10% dissolve with methanol, adopt the ODS-C18 post that it is separated, at first use 2～10% methanol as mobile phase, get eluent fr.7, change 40～80% methanol then, get eluent fr.8 as mobile phase, use 100% methanol solution as mobile phase at last, get eluent fr.9;
(3) preparation separating technology: separate fr.5 and fr.8 with preparative liquid chromatography; Chromatographic column is semi-preparative column (LichrospherC18; 10.0mm * 250mm, 5 μ m), mobile phase is water and acetonitrile, and gradient elution, flow velocity are 3ml/min, and column temperature is that room temperature is collected fraction in the corresponding time period, obtains through further isolating each component.
3. Cortex Moutan as claimed in claim 2 extracts, the separation criterion method, comprises the steps:
(1) extraction process: take by weighing the Cortex Moutan medical material, with its grinding and sieving, adding 8 times of amount volume ratios then is 1: 1 ethyl acetate and ethanol, and reflux 1 hour is extracted 2 times, and merging filtrate gets extracting solution fr.1; Add 8 times of amount 70% ethanol in medicinal residues, reflux 1 hour is extracted 2 times, and merging filtrate gets extracting solution fr.2; Add entry in medicinal residues at last, reflux 1 hour is extracted 2 times, and merging filtrate gets extracting solution fr.3;
(2) separating technology: fr.1 is condensed into extractum with extracting solution, use silica gel mixed sample, adopt normal phase silicagel column that it is separated, be that 50: 1 petroleum ether and ethyl acetate are as mobile phase at first with volume ratio, eluent fr.4, change volume ratio then and be 10: 1 chloroform and methanol as mobile phase, eluent fr.5, use methanol as mobile phase at last, get eluent fr.6; Fr.2 is condensed into extractum with extracting solution, with sample on 5% dissolve with methanol, adopt the ODS-C18 post that it is separated, at first use 5% methanol as mobile phase, get eluent fr.7, change 60% methanol then, get eluent fr.8 as mobile phase, use 100% methanol solution as mobile phase at last, get eluent fr.9;
(3) preparation separating technology: continue to separate fr.5 and fr.8 with preparative liquid chromatography;
The fr.5 separation condition: chromatographic column is semi-preparative column (the Lichrospher C18 of Chinese nation; 10.0mm * 250mm, 5 μ m), mobile phase is water (A) and acetonitrile (B), and flow velocity is 3ml/min, and column temperature is a room temperature, and the gradient elution program is as follows:
In the time of 0 minute, mobile phase A is that 80% aqueous solution, Mobile phase B are 20% acetonitrile solution;
In the time of 40 minutes, mobile phase A is that 20% aqueous solution, Mobile phase B are 80% acetonitrile solution;
In the time of 50 minutes, mobile phase A is that 5% aqueous solution, Mobile phase B are 95% acetonitrile solution;
The fr.5 separating resulting: the component and the corresponding acquisition time that are obtained by the preparative liquid chromatography separation are as follows:
4.0 collected and obtain component fr.51 in～7.6 minutes, 7.6 collected and obtain component fr.52 in～9.7 minutes, 9.7 collected and obtain component fr.53 in～14.2 minutes, 14.2 collected and obtain component fr.54 in～18.4 minutes, 21.8 collected and obtain component fr.55 in～26.5 minutes, collection in 21.8～26.5 minutes obtains component fr.56, collection in 26.5～30.3 minutes obtains component fr.57,30.3 collected and obtain component fr.58 in～35.5 minutes, collection in 35.5～45 minutes obtains component fr.59;
The fr.8 separation condition: chromatographic column is semi-preparative column (the Lichrospher C18 of Chinese nation; 10.0mm * 250mm, 5 μ m), mobile phase is water (A) and acetonitrile (B), and flow velocity is 3ml/min, and column temperature is a room temperature, and the gradient elution program is as follows:
In the time of 0 minute, mobile phase A is that 90% aqueous solution, Mobile phase B are 10% acetonitrile solution;
In the time of 8 minutes, mobile phase A is that 81% aqueous solution, Mobile phase B are 19% acetonitrile solution;
In the time of 60 minutes, mobile phase A is that 65% aqueous solution, Mobile phase B are 35% acetonitrile solution;
In the time of 70 minutes, mobile phase A is that 95% aqueous solution, Mobile phase B are 5% acetonitrile solution;
The fr.8 separating resulting: the component and the corresponding acquisition time that are obtained by the preparative liquid chromatography separation are as follows: collection in 4.0～7.7 minutes obtains component fr.81,7.7 collected and obtain component fr.82 in～10.7 minutes, 10.7 collected and obtain component fr.83 in～15.8 minutes, 15.8 collected and obtain component fr.84 in～18.8 minutes, 18.8 collected and obtain component fr.85 in～23.2 minutes, 23.2 collected and obtain component fr.86 in～27.4 minutes, 27.4 collected and obtain component fr.87 in～33.1 minutes, 33.1 collected and obtain component fr.88 in～40.2 minutes, 40.2 collected and obtain component fr.89 in～44.4 minutes, 44.4 collected and obtain component fr.810 in～48.5 minutes, 48.5 collected and obtain component fr.811 in～58 minutes, collected in 58～67 minutes and obtain component fr.812, collection in 67～75 minutes obtains component fr.813.
4. Cortex Moutan as claimed in claim 3 extracts, the separation criterion method, it is characterized in that:
Main compound is Paeoniflorin among the component fr.51, Gallic Acid;
Main compound is Paeoniflorin among the component fr.52, Gallic Acid;
Main compound is Paeoniflorin among the component fr.53;
Main compound is Galloyl-Paeoniflorin among the component fr.54, Mudanpioside h, Paeoniflorin;
Main compound is Mudanpioside c among the component fr.55, Benzoyloxypaeoni florin;
Main compound is Benzoylpaeoniflorin among the component fr.56.
5. Cortex Moutan as claimed in claim 3 extracts, the separation criterion method, it is characterized in that:
Main compound is Paeonidanin among the component fr.81, Mudanoside b;
Main compound is Paeonidanin among the component fr.82, Mudanoside b;
Main compound is Oxypaeoniflorin among the component fr.83;
Main compound is Oxypaeoniflorin among the component fr.84;
Main compound is Paeoniflorin among the component fr.85;
Main compound is 1,2,3 among the component fr.86,6-tetra-O-galloyl-β-D-glucose, Suffruticoside a or Suffruticoside b or Suffruticoside c or Suffruticoside d;
Main compound is Galloyl-Paeoniflorin among the component fr.87;
Main compound is Digalloyl-1 among the component fr.88,2,3, and 4-tetra-O-galloyl--D-glucopyranose;
Main compound is 1,2,3,4 among the component fr.89,6-Pentagalloylglucose, Digalloyl-1,2,3,4-tetra-O-galloyl--D-glucopyranose;
Main compound is Mudanpioside c among the component fr.810, Benzoyloxypaeoniflorin;
Main compound is Benzoyloxypaeoniflorin among the component fr.811;
Main compound is Benzoylpaeoniflorin among the component fr.812.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100122758A CN1903259B (en) | 2005-07-29 | 2005-07-29 | Method for extraction and separation of moutan bark |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100122758A CN1903259B (en) | 2005-07-29 | 2005-07-29 | Method for extraction and separation of moutan bark |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1903259A true CN1903259A (en) | 2007-01-31 |
| CN1903259B CN1903259B (en) | 2011-11-30 |
Family
ID=37672719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005100122758A Expired - Fee Related CN1903259B (en) | 2005-07-29 | 2005-07-29 | Method for extraction and separation of moutan bark |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1903259B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103087128A (en) * | 2013-02-05 | 2013-05-08 | 菏泽尧舜牡丹生物科技有限公司 | Method for extracting paeoniflorin from peony seed meal |
| CN104231012A (en) * | 2013-06-06 | 2014-12-24 | 复旦大学 | Phenolic glycoside compounds and application thereof in preparation of anticomplement drugs |
| CN104231019A (en) * | 2013-06-06 | 2014-12-24 | 复旦大学 | Application of monoterpene glycoside compounds in preparation of anticomplement drugs |
| CN105726646A (en) * | 2016-03-08 | 2016-07-06 | 青岛市中心医院 | Medicine composition for treating rheumatoid arthritis through immune adjustment and preparation method of medicine composition |
-
2005
- 2005-07-29 CN CN2005100122758A patent/CN1903259B/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103087128A (en) * | 2013-02-05 | 2013-05-08 | 菏泽尧舜牡丹生物科技有限公司 | Method for extracting paeoniflorin from peony seed meal |
| CN103087128B (en) * | 2013-02-05 | 2015-09-02 | 菏泽尧舜牡丹生物科技有限公司 | A kind of method extracting peoniflorin from the peony seeds dregs of rice |
| CN104231012A (en) * | 2013-06-06 | 2014-12-24 | 复旦大学 | Phenolic glycoside compounds and application thereof in preparation of anticomplement drugs |
| CN104231019A (en) * | 2013-06-06 | 2014-12-24 | 复旦大学 | Application of monoterpene glycoside compounds in preparation of anticomplement drugs |
| CN104231019B (en) * | 2013-06-06 | 2017-05-10 | 复旦大学 | Application of monoterpene glycoside compounds in preparation of anticomplement drugs |
| CN104231012B (en) * | 2013-06-06 | 2017-05-31 | 复旦大学 | Phenol glycosides compound and its purposes in anticomplement medicament is prepared |
| CN105726646A (en) * | 2016-03-08 | 2016-07-06 | 青岛市中心医院 | Medicine composition for treating rheumatoid arthritis through immune adjustment and preparation method of medicine composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1903259B (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1903250A (en) | Method for extraction and separation of red rooted salvia | |
| CN101073606A (en) | Method for separating and extracting white Peony Root | |
| CN101073592A (en) | Method for separating and extracting Milkvetch Root | |
| CN102416139B (en) | Chinese medicine composition for treating breast diseases | |
| CN1806846A (en) | Chinese medicinal composition, its preparation process and quality control method | |
| WO2009117953A1 (en) | Pharmaceutical composition having antidepressive, antianxious action and preparation method thereof | |
| CN106324174A (en) | Quality standard for traditional Chinese medicine formula granules | |
| CN101073587A (en) | Method for separating and extracting Chinese Thorowax Root | |
| CN1903241A (en) | Method for extraction and separation of pseudo-ginseng | |
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN1903239A (en) | Method for extraction and separation of rhizome of chuanixong | |
| CN101073623A (en) | Method for separating and extracting cattail pollen | |
| CN104288245B (en) | Anti-aging and constitutional pharmaceutical composition and preparation method thereof and detection method | |
| CN101239166B (en) | Blood-regulating and face-nourishing capsule and preparation thereof | |
| CN1903259A (en) | Method for extraction and separation of moutan bark | |
| CN102302609A (en) | Compound traditional Chinese drug preparation for improving subhealth | |
| CN109224038B (en) | Traditional Chinese medicine composition containing channel-inducing medicine evodia rutaecarpa for treating blood stasis collateral blocking type hepatic fibrosis and preparation method and application thereof | |
| CN1923263A (en) | Traditional Chinese medicine composition, its preparing method and quality controlling means | |
| CN104740521B (en) | Preparation method of Ganfule soft capsule | |
| CN1903279A (en) | Method for extraction and separation of Immature Bitter orange | |
| CN106177345A (en) | QIJU DIHUANG WAN and preparation method thereof | |
| CN102058765A (en) | Chinese medicine preparation for treating cirrhosis and preparation method thereof | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN104771595A (en) | Chinese medicinal composition for enhancing immunity and preparation method thereof | |
| CN103263581A (en) | Shuangshen capsule for reducing blood sugar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070511 Address after: Hedong District of Beichen Puji road in Tianjin No. 2 city of the modern Chinese Medicine Applicant after: Tianjin Tianshili Pharmaceutical Co., Ltd. Address before: Beichen Xinyi Road white Tianjin Liaohe Road No. 1 Applicant before: Tianshili Modern Traditional Chinese Medicine Research & Devleopment Co., Ltd., |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TIANSHILI PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111130 Termination date: 20190729 |